ABSTRACT
The host cell membrane-associated RING-CH 8 protein (MARCH8), a member of the E3 ubiquitin ligase family, regulates intracellular turnover of many transmembrane proteins and shows potent antiviral activities. Generally, 2 antiviral modes are performed by MARCH8. On the one hand, MARCH8 catalyzes viral envelope glycoproteins (VEGs) ubiquitination and thus leads to their intracellular degradation, which is the cytoplasmic tail (CT)-dependent (CTD) mode. On the other hand, MARCH8 traps VEGs at some intracellular compartments (such as the trans-Golgi network, TGN) but without inducing their degradation, which is the cytoplasmic tail-independent (CTI) mode, by which MARCH8 hijacks furin, a cellular proprotein convertase, to block VEGs cleavage. In addition, the MARCH8 C-terminal tyrosine-based motif (TBM) 222YxxL225 also plays a key role in its CTI antiviral effects. In contrast to its antiviral potency, MARCH8 is occasionally hijacked by some viruses and bacteria to enhance their invasion, indicating a duplex role of MARCH8 in host pathogenic infections. This review summarizes MARCH8's antiviral roles and how viruses evade its restriction, shedding light on novel antiviral therapeutic avenues.
Subject(s)
Virus Diseases , Humans , Antiviral Agents/pharmacology , CD40 Ligand , Membrane Proteins , Tyrosine , Viral Envelope ProteinsABSTRACT
The unfavorable prognosis of many neurological conditions could be attributed to limited tissue regeneration in central nervous system (CNS) and overwhelming inflammation, while liver X receptor (LXR) may regulate both processes due to its pivotal role in cholesterol metabolism and inflammatory response, and thus receives increasing attentions from neuroscientists and clinicians. Here, we summarize the signal transduction of LXR pathway, discuss the therapeutic potentials of LXR agonists based on preclinical data using different disease models, and analyze the dilemma and possible resolutions for clinical translation to encourage further investigations of LXR related therapies in CNS disorders.
Subject(s)
Central Nervous System Diseases , Orphan Nuclear Receptors , Humans , Liver X Receptors , Orphan Nuclear Receptors/metabolism , Central Nervous System/metabolism , Inflammation , Central Nervous System Diseases/drug therapyABSTRACT
Membrane-associated RING-CH (MARCH) family proteins were recently reported to inhibit viral replication through multiple modes. Previous work showed that human MARCH8 blocked Ebola virus (EBOV) glycoprotein (GP) maturation. Our study here demonstrates that human MARCH1 and MARCH2 share a similar pattern to MARCH8 in restricting EBOV GP-pseudotyped viral infection. Human MARCH1 and MARCH2 retain EBOV GP at the trans-Golgi network, reduce its cell surface display, and impair EBOV GP-pseudotyped virions infectivity. Furthermore, we uncover that the host proprotein convertase furin could interact with human MARCH1/2 and EBOV GP intracellularly. Importantly, the furin P domain is verified to be recognized by MARCH1/2/8, which is critical for their blocking activities. Besides, bovine MARCH2 and murine MARCH1 also impair EBOV GP proteolytic processing. Altogether, our findings confirm that MARCH1/2 proteins of different mammalian origins showed a relatively conserved feature in blocking EBOV GP cleavage, which could provide clues for subsequent MARCHs antiviral studies and may facilitate the development of novel strategies to antagonize enveloped virus infection.
Subject(s)
Ebolavirus , Hemorrhagic Fever, Ebola , Animals , Cattle , Humans , Mice , Cell Line , Furin/metabolism , Glycoproteins , Mammals/metabolism , Membrane Proteins/metabolism , Ubiquitin-Protein Ligases/metabolism , Viral Envelope/metabolism , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolismABSTRACT
In this study, we synthesized a novel Co(II)-containing coordination compound (CP) [Co2(MMBA)2(HPT)2(H2O)2]·2H2O (1) through a solvothermal reaction of Co(NO3)6·6H2O with 3-(pyridin-2-yl)-1 H-1,2,4-triazole (HPT) and 2-(4-methylbenzoyl)benzoic acid (HMMBA). Fluorescence spectroscopy confirmed that this compound exhibited superior blue fluorescence properties compared to the original ligands. Further, aspirin (ASA) was loaded onto this CP via physical adsorption to create CP-ASA. Interestingly, the fluorescence properties of the CP decreased with the loading of the drug but were restored upon drug release. Leveraging the unique optical properties and biocompatibility of Polymer Liquid Crystal (PLC), we further encapsulated CP-ASA, forming the CP-PLC@ASA composite. The target product was confirmed through various characterization techniques including Elemental Analysis (EA), Fourier-Transform Infrared Spectroscopy (FT-IR), Powder X-Ray Diffraction (PXRD), and Thermogravimetric Analysis (TGA). Moreover, the biological activity of this composite was evaluated in vitro for osteoarthritis, and its potential mechanisms were explored.
ABSTRACT
Stroke is the second leading cause of death worldwide and has two major subtypes: ischemic stroke and hemorrhagic stroke. Neuroinflammation is a pathological hallmark of ischemic stroke and intracerebral hemorrhage (ICH), contributing to the extent of brain injury but also in its repair. Neuroinflammation is intricately linked to the extracellular matrix (ECM), which is profoundly altered after brain injury and in aging. In the early stages after ischemic stroke and ICH, immune cells are involved in the deposition and remodeling of the ECM thereby affecting processes such as blood-brain barrier and cellular integrity. ECM components regulate leukocyte infiltration into the central nervous system, activate a variety of immune cells, and induce the elevation of matrix metalloproteinases (MMPs) after stroke. In turn, excessive MMPs may degrade ECM into components that are pro-inflammatory and injurious. Conversely, in the later stages after stroke, several ECM molecules may contribute to tissue recovery. For example, thrombospondin-1 and biglycan may promote activity of regulatory T cells, inhibit the synthesis of proinflammatory cytokines, and aid regenerative processes. We highlight these roles of the ECM in ischemic stroke and ICH and discuss their potential cellular and molecular mechanisms. Finally, we discuss therapeutics that could be considered to normalize the ECM in stroke. Our goal is to spur research on the ECM in order to improve the prognosis of ischemic stroke and ICH.
Subject(s)
Brain Injuries , Ischemic Stroke , Stroke , Humans , Neuroinflammatory Diseases , Cerebral Hemorrhage , Extracellular MatrixABSTRACT
TANK-binding kinase 1 (TBK1) is crucial in producing type â interferons (IFN-â ) that play critical functions in antiviral innate immunity. The tight regulation of TBK1, especially its activation, is very important. Here we identify NLRC4 as a positive regulator of TBK1. Ectopic expression of NLRC4 facilitates the activation of the IFN-ß promoter, the mRNA levels of IFN-ß, ISG54, and ISG56, and the nuclear translocation of interferon regulatory factor 3 induced by cGAS and STING. Consistently, under herpes simplex virus-1 (HSV-1) infection, knockdown or knockout of NLRC4 in BJ cells and primary peritoneal macrophages from Nlrc4-deficient (Nlrc4-/- ) mice show attenuated Ifn-ß, Isg54, and Isg56 mRNA transcription, TBK1 phosphorylation, and augmented viral replications. Moreover, Nlrc4-/- mice show higher mortality upon HSV-1 infection. Mechanistically, NLRC4 facilitates the interaction between TBK1 and the E3 ubiquitin ligase CBL to enhance the K63-linked polyubiquitination of TBK1. Our study elucidates a previously uncharacterized function for NLRC4 in upregulating the cGAS-STING signaling pathway and antiviral innate immunity.
Subject(s)
Herpes Simplex , Herpesvirus 1, Human , Signal Transduction , Animals , Mice , Antiviral Agents/metabolism , Herpes Simplex/genetics , Herpesvirus 1, Human/genetics , Immunity, Innate , Nucleotidyltransferases/genetics , Nucleotidyltransferases/metabolism , Phosphorylation , Signal Transduction/genetics , UbiquitinationABSTRACT
The coronavirus disease 2019 (COVID-19) continues to pose a major threat to public health worldwide. Although many studies have clarified the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection process, the underlying mechanisms of viral invasion and immune evasion were still unclear. This study focused on SARS-CoV-2 ORF7a (open reading frame-7a), one of the essential open reading frames (ORFs) in infection and pathogenesis. First, by analyzing its physical and chemical characteristics, SARS-CoV-2 ORF7a is an unstable hydrophobic transmembrane protein. Then, the ORF7a transmembrane domain three-dimensional crystal structure model was predicted and verified. SARS-CoV-2 ORF7a localized in the endoplasmic reticulum and participated in the autophagy-lysosome pathway via interacting with p62. In addition, we elucidated the underlying molecular mechanisms by which ORF7a intercepted autophagic flux, promoted double membrane vesicle formation, and evaded host autophagy-lysosome degradation and antiviral innate immunity. This study demonstrated that ORF7a could be a therapeutic target, and Glecaprevir may be a potential drug against SARS-CoV-2 by targeting ORF7a. A comprehensive understanding of ORF7a's functions may contribute to developing novel therapies and clinical drugs against COVID-19.
Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Autophagosomes , Autophagy , LysosomesABSTRACT
Varicella is a highly prevalent infectious disease with a similar transmission pathway to coronavirus disease 2019 (COVID-19). In the context of the COVID-19 pandemic, anti-COVID-19 nonpharmaceutical interventions (NPIs) have been implemented to prevent the spread of the infection. This study aims to analyze varicella's epidemiological characteristics and further investigate the effect of anti-COVID-19 NPIs on varicella in Xi'an, northwestern China. Based on the varicella surveillance data, search engine indices, meteorological factors from 2011 to 2021 in Xi'an, and different levels of emergency response to COVID-19 during the pandemic, we applied Bayesian Structural Time Series models and interrupted time series analysis to predict the counterfactual incidence of varicella and quantify the impact of varying NPIs intensities on varicella. From 2011 to 2021, varicella incidence increased, especially in 2019, with a high incidence of 111.69/100 000. However, there was a sharp decrease of 43.18% in 2020 compared with 2019, and the peak of varicella incidence in 2020 was lower than in previous years from the 21st to the 25th week. In 2021, the seasonality of varicella incidence gradually returned to a seasonal pattern in 2011-2019. The results suggest that anti-COVID-19 NPIs effectively reduce the incidence of varicella, and the reduction has spatiotemporal heterogeneity.
Subject(s)
COVID-19 , Chickenpox , Humans , Chickenpox/epidemiology , Chickenpox/prevention & control , Pandemics/prevention & control , Prevalence , Bayes Theorem , COVID-19/epidemiology , COVID-19/prevention & controlABSTRACT
Cerebral ischemia causes great damage to ischemic brain regions. Remote limb post-conditioning (RLIPostC) has neuroprotective effects on cerebral ischemia. Paired immunoglobulin receptor B (PirB) has been confirmed to affect the cerebral ischemia injury. Therefore, this study investigated the mechanism of RLIPostC on cerebral ischemia injury. The middle cerebral artery occlusion (MCAO) model was established in rats, followed by RLIPostC (by blocking the blood flow in the distal limb for 10 min after MCAO, and restored for 10 min, three cycles), or in vivo lentivirus infection of miR-21-5p agomir, sh-PirB and oe-PirB. The locomotor abilities were assessed using the foot fault test and balance beam walking test at 48 h, 7 and 21 days after operation, and neurological function was measured on day 21. The cerebral infarct area, Nissl bodies and the pathology of brain tissues were examined using histological staining, followed by the assessment of miR-21-5p and PirB levels and the binding relationship between miR-21-5p and PirB. miR-21-5p was poorly expressed in MCAO rats. Both RLIPostC and overexpression of miR-21-5p reduced motor dysfunction, neurological function score, cerebral infarction area and brain edema; increased Nissl bodies in MCAO rats and thus alleviated the brain damage caused by cerebral ischemia. RLIPostC promoted miR-21-5p expression. PirB was highly expressed in cerebral ischemia, and miR-21-5p targeted PirB. Overall, RLIPostC promotes miR-21-5p expression and then inhibits PirB to alleviate cerebral ischemia injury, which provides theoretical basis for basic research on motor dysfunction and neuron injury after cerebral ischemia and the development of neuroscience.
Subject(s)
Brain Ischemia , Ischemic Postconditioning , MicroRNAs , Reperfusion Injury , Animals , Brain/metabolism , Brain Ischemia/metabolism , Infarction, Middle Cerebral Artery/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Rats , Receptors, Immunologic , Reperfusion Injury/metabolismABSTRACT
Extracellular matrix metalloproteinase inducer (EMMPRIN) has been shown to be a vital inflammatory mediator in several neurological and neurodegenerative diseases. However, the role of EMMPRIN in intracerebral hemorrhage (ICH) remains unexplored. In this study, we aimed to exploit a highly selective monoclonal anti-EMMPRIN antibody to functionally inhibit EMMPRIN activity and thus that of MMPs as the downstream effector. To induce ICH pathology, adult C57BL/6 male mice were injected with collagenase type VII or saline as control into the right basal ganglia and were euthanized at different time points. The anti-EMMPRIN monoclonal antibody was intravenously injected once daily for 3 days to block the expression of EMMPRIN initiating at 4 h post-ICH. Western blot and immunofluorescence analysis results revealed that EMMPRIN expression was significantly increased surrounding the hematoma at 3 and 7 d time points after ICH when compared to the saline treated control group. EMMPRIN expression was co-localized with GFAP (astrocytes) and Iba1 (microglia) at 3 d time point post-ICH, but not in the control group mice. The co-localization of EMMPRIN with CD31 in endothelial cells occurred in both groups and was higher in the ICH brain. However, EMMPRIN expression was not detected in neurons from either group. The inhibition of EMMPRIN reduced the expression of MMP-9, the number of infiltrated neutrophils, the degree of brain injury and promoted neurological recovery after ICH. In conclusion, EMMPRIN could mediate the upregulation of MMP-9 and exacerbate neurological dysfunction in a mouse model of experimental ICH. Furthermore, blocking EMMPRIN reduced brain injury and subsequently promoted neurological recovery in ICH mice brains. These outcomes highlight that inhibition of EMMPRIN can be a potential therapeutic intervention strategy to regulate MMP-9's pathological roles during ICH.
Subject(s)
Basigin , Brain Injuries , Cerebral Hemorrhage , Matrix Metalloproteinase 9 , Animals , Basigin/metabolism , Brain Injuries/pathology , Cerebral Hemorrhage/pathology , Disease Models, Animal , Endothelial Cells/metabolism , Male , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Inbred C57BLABSTRACT
Remote ischemic preconditioning (RiPC) is the process where preconditioning ischemia protects the organs against the subsequent index ischemia. RiPC is a protective method for brain damage. This study is to explore the effect and mechanism of RiPC in cerebral ischemia injury in rats through regulation of miR-204-5p/BRD4 expression. Middle cerebral artery occlusion (MCAO) rat model and glucose deprivation (OGD) neuron model were established. The effect of RiPC on neurological deficits, cerebral infarct size, autophagy marker, inflammatory cytokines and apoptosis was evaluated. miR-204-5p expression was analyzed using RT-qPCR, and then downregulated using miR-204-5p antagomir to estimate its effect on MCAO rats. The downstream mechanism of miR-204-5p was explored. RiPC promoted autophagy, reduced cerebral infarct volume and neurological deficit score, and alleviated apoptosis and cerebral ischemia injury in rats, with no significant effects on healthy rat brains. RiPC up-regulated miR-204-5p expression in MCAO rats. miR-204-5p knockdown partially reversed the effect of RiPC. RiPC promoted autophagy in OGD cells, and attenuated inflammation and apoptosis. miR-204-5p targeted BRD4, which partially reversed the effect of miR-204-5p on OGD cells. RiPC activated the PINK1/Parkin pathway via the miR-204-5p/BRD4 axis. In conclusion, RiPC activated the PINK1/Parkin pathway and prevented cerebral ischemia injury by up-regulating miR-204-5p and inhibiting BRD4.
Subject(s)
Brain Ischemia , Ischemic Preconditioning , MicroRNAs , Reperfusion Injury , Animals , Brain Ischemia/genetics , Brain Ischemia/metabolism , Brain Ischemia/prevention & control , Infarction, Middle Cerebral Artery/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Nuclear Proteins/metabolism , Protein Kinases/metabolism , Rats , Rats, Sprague-Dawley , Reperfusion Injury/metabolism , Signal Transduction , Transcription Factors , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/metabolismABSTRACT
Biological rhythms regulate physiological activities. Shiftwork disrupts normal circadian rhythms and may increase the risk of cancer through unknown mechanisms. To mimic environmental light/dark changes encountered by shift workers, a protocol called 'chronic jet lag (CJL)' induced by repeatedly shifting light-dark cycles has been used. Here, we subjected mice to CJL by advancing light-dark cycle by 6 h every 2 days, and conducted RNA sequencing to analyze the expression profile and molecular signature in the brain areas of prefrontal cortex and nucleus accumbens. We also performed positron emission tomography (PET) imaging to monitor changes related to glucose metabolism in brain. Our results reveal systematic reprogramming of gene expression associated with cancer-related pathways and metabolic pathways in prefrontal cortex and nucleus accumbens. PET imaging indicates that glucose uptake level was significantly reduced in whole brain as well as the individual brain regions. Moreover, qPCR analysis describes that the expression levels of cancer-related genes were altered in prefrontal cortex and nucleus accumbens. Overall, these results suggest a molecular and metabolic link with CJL-mediated cancer risk, and generate hypotheses on how CJL increases the susceptibility to cancer.
Subject(s)
Biomarkers, Tumor/metabolism , Brain Neoplasms/pathology , Gene Expression Regulation, Neoplastic , Jet Lag Syndrome/complications , Nucleus Accumbens/pathology , Photoperiod , Prefrontal Cortex/pathology , Animals , Biomarkers, Tumor/genetics , Brain Neoplasms/etiology , Brain Neoplasms/metabolism , Chronic Disease , Disease Models, Animal , Male , Mice , Mice, Inbred C57BL , Nucleus Accumbens/metabolism , Prefrontal Cortex/metabolism , RNA-SeqABSTRACT
The prognosis of intracerebral haemorrhage continues to be devastating despite much research into this condition. A prominent feature of intracerebral haemorrhage is neuroinflammation, particularly the excessive representation of pro-inflammatory CNS-intrinsic microglia and monocyte-derived macrophages that infiltrate from the circulation. The pro-inflammatory microglia/macrophages produce injury-enhancing factors, including inflammatory cytokines, matrix metalloproteinases and reactive oxygen species. Conversely, the regulatory microglia/macrophages with potential reparative and anti-inflammatory roles are outcompeted in the early stages after intracerebral haemorrhage, and their beneficial roles appear to be overwhelmed by pro-inflammatory microglia/macrophages. In this review, we describe the activation of microglia/macrophages following intracerebral haemorrhage in animal models and clinical subjects, and consider their multiple mechanisms of cellular injury after haemorrhage. We review strategies and medications aimed at suppressing the pro-inflammatory activities of microglia/macrophages, and those directed at elevating the regulatory properties of these myeloid cells after intracerebral haemorrhage. We consider the translational potential of these medications from preclinical models to clinical use after intracerebral haemorrhage injury, and suggest that several approaches still lack the experimental support necessary for use in humans. Nonetheless, the preclinical data support the use of deactivator or inhibitor of pro-inflammatory microglia/macrophages, whilst enhancing the regulatory phenotype, as part of the therapeutic approach to improve the prognosis of intracerebral haemorrhage.
Subject(s)
Cerebral Hemorrhage/immunology , Inflammation/immunology , Macrophages/immunology , Microglia/immunology , Animals , Humans , PhenotypeABSTRACT
The new decade of the 21st century (2020) started with the emergence of a novel coronavirus known as SARS-CoV-2 that caused an epidemic of coronavirus disease (COVID-19) in Wuhan, China. It is the third highly pathogenic and transmissible coronavirus after severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in humans. The source of origin, transmission to humans, and mechanisms associated with the pathogenicity of SARS-CoV-2 are not yet clear, however, its resemblance to SARS-CoV and several other bat coronaviruses was recently confirmed through genome sequencing-related studies. The development of therapeutic strategies is necessary in order to prevent further epidemics and cure infections. In this review, we summarize current information about the emergence, origin, diversity, and epidemiology of three pathogenic coronaviruses with a specific focus on the current outbreak in Wuhan, China. Furthermore, we discuss the clinical features and potential therapeutic options that may be effective against SARS-CoV-2.
Subject(s)
Betacoronavirus/genetics , Betacoronavirus/pathogenicity , Coronavirus Infections/therapy , Coronavirus Infections/virology , Pneumonia, Viral/therapy , Pneumonia, Viral/virology , Zoonoses/therapy , Zoonoses/virology , Animals , COVID-19 , China/epidemiology , Coronavirus Infections/epidemiology , Coronavirus Infections/pathology , Disease Outbreaks , Genetic Variation , Genome, Viral/genetics , Humans , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/pathology , SARS-CoV-2 , Zoonoses/epidemiology , Zoonoses/pathologyABSTRACT
BACKGROUND: Noncontrast computed tomography (CT) markers are increasingly used for predicting hematoma expansion. The aim of our study was to investigate the predictive value of expansion-prone hematoma in predicting hematoma expansion and outcome in patients with intracerebral hemorrhage (ICH). METHODS: Between July 2011 and January 2017, ICH patients who underwent baseline CT scan within 6 h of symptoms onset and follow-up CT scan were recruited into the study. Expansion-prone hematoma was defined as the presence of one or more of the following imaging markers: blend sign, black hole sign, or island sign. The diagnostic performance of blend sign, black hole sign, island sign, and expansion-prone hematoma in predicting hematoma expansion was assessed. Predictors of hematoma growth and poor outcome were analyzed using multivariable logistical regression analysis. RESULTS: A total of 282 patients were included in our final analysis. Of 88 patients with early hematoma growth, 69 (78.4%) had expansion-prone hematoma. Expansion-prone hematoma had a higher sensitivity and accuracy for predicting hematoma expansion and poor outcome when compared with any single imaging marker. After adjustment for potential confounders, expansion-prone hematoma independently predicted hematoma expansion (OR 28.33; 95% CI 12.95-61.98) and poor outcome (OR 5.67; 95% CI 2.82-11.40) in multivariable logistic model. CONCLUSION: Expansion-prone hematoma seems to be a better predictor than any single noncontrast CT marker for predicting hematoma expansion and poor outcome. Considering the high risk of hematoma expansion in these patients, expansion-prone hematoma may be a potential therapeutic target for anti-expansion treatment in future clinical studies.
Subject(s)
Cerebral Hemorrhage/pathology , Disease Progression , Hematoma/pathology , Outcome Assessment, Health Care , Adult , Aged , Aged, 80 and over , Cerebral Hemorrhage/diagnostic imaging , Female , Follow-Up Studies , Hematoma/diagnostic imaging , Humans , Male , Middle Aged , Tomography, X-Ray ComputedSubject(s)
Ebolavirus , Hemorrhagic Fever, Ebola , Animals , Humans , Hemorrhagic Fever, Ebola/epidemiology , Disease OutbreaksABSTRACT
A recent study published in mBio by Cao et al. revealed the crucial roles of bacteria in benefitting SARS-CoV-2 mutations (B. Cao, X. Wang, W. Yin, Z. Gao, and B. Xia, mBio e3187-23, 2024, https://doi.org/10.1128/mbio.03187-23). Understanding the underlying mechanisms driving the evolution of SARS-CoV-2 is crucial for predicting the future trajectory of the COVID-19 pandemic and developing preventive and treatment strategies. This study provides important insights into the rapid and complex evolution of viruses facilitated by bacterial-virus interactions.
Subject(s)
Bacteria , COVID-19 , Mutation , SARS-CoV-2 , SARS-CoV-2/genetics , COVID-19/virology , COVID-19/microbiology , Humans , Bacteria/genetics , Bacteria/classification , Evolution, MolecularABSTRACT
The quick progress of epigenetic study has kindled new hope for treating many cancers. When it comes to RNA epigenetics, the ac4C acetylation modification is showing promise, whereas N-acetyltransferase 10 plays a wide range of biological functions, has a significant impact on cellular life events, and is frequently highly expressed in many malignant tumors. N-acetyltransferase 10 is an acetyltransferase with important biological involvement in cellular processes and lifespan. Because it is highly expressed in many malignant tumors, it is considered a pro-carcinogenic gene. The review aims to introduce NAT10, summarize the effects of ac4C acetylation on tumor growth from multiple angles, and discuss the possible therapeutic targeting of NAT10 and the future directions of ac4C acetylation investigations.
Subject(s)
Neoplasms , RNA , Humans , Acetylation , Acetyltransferases , Carcinogenesis/genetics , Cell Transformation, Neoplastic , Neoplasms/genetics , N-Terminal Acetyltransferases/genetics , N-Terminal Acetyltransferases/metabolismABSTRACT
Rhythmicity of the circadian system is a 24-hour period, driven by transcription-translation feedback loops of circadian clock genes. The central circadian pacemaker in mammals is located in the hypothalamic suprachiasmatic nucleus (SCN), which controls peripheral circadian clocks. In general, most physiological processes are regulated by the circadian system, which is modulated by environmental cues such as exposure to light and/or dark, temperature, and the timing of sleep/wake and food intake. The chronic circadian disruption caused by shift work, jetlag, and/or irregular sleep-wake cycles has long-term health consequences. Its dysregulation contributes to the risk of psychiatric disorders, sleep abnormalities, hypothyroidism and hyperthyroidism, cancer, and obesity. A number of neurological conditions may be worsened by changes in the circadian clock via the SCN pacemaker. For stroke, different physiological activities such as sleep/wake cycles are disrupted due to alterations in circadian rhythms. Moreover, the immunological processes that affect the evolution and recovery processes of stroke are regulated by the circadian clock or core-clock genes. Thus, disrupted circadian rhythms may increase the severity and consequences of stroke, while readjustment of circadian clock machinery may accelerate recovery from stroke. In this manuscript, we discuss the relationship between stroke and circadian rhythms, particularly on stroke development and its recovery process. We focus on immunological and/or molecular processes linking stroke and the circadian system and suggest the circadian rhythm as a target for designing effective therapeutic strategies in stroke.